Cargando…

Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease

BACKGROUND AND AIMS: Progressive liver fibrosis related to non‐alcoholic fatty liver disease (NAFLD) is associated with all‐cause and liver‐related mortality. We assessed vibration‐controlled transient elastography (VCTE) as a predictor of mortality. METHOD: Data from patients who underwent VCTE for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braude, Michael, Roberts, Stuart, Majeed, Ammar, Lubel, John, Prompen, Jirayut, Dev, Anouk, Sievert, William, Bloom, Stephen, Gow, Paul, Kemp, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Metabolic & Toxic Liver Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086842/ https://www.ncbi.nlm.nih.gov/pubmed/36050821 http://dx.doi.org/10.1111/liv.15415

Ejemplares similares

Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two‐dimensional shear wave elastography in non‐alcoholic fatty liver disease
por: Mendoza, Yuly P., et al.
Publicado: (2021)

Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease
por: Flores‐Guerrero, Jose L., et al.
Publicado: (2021)

Oxidative stress is associated with suspected non‐alcoholic fatty liver disease and all‐cause mortality in the general population
por: Damba, Turtushikh, et al.
Publicado: (2020)

Inhibition of polyploidization in Pten‐deficient livers reduces steatosis
por: Moreno, Eva, et al.
Publicado: (2022)

Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial
por: George, Elena S., et al.
Publicado: (2022)

Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease
por: Sangineto, Moris, et al.
Publicado: (2020)

Impact of osteopontin on the development of non‐alcoholic liver disease and related hepatocellular carcinoma
por: Nardo, Alexander D., et al.
Publicado: (2020)

Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH
por: Bruschi, Francesca V., et al.
Publicado: (2020)

The endothelial function biomarker soluble E‐selectin is associated with nonalcoholic fatty liver disease
por: Simons, Nynke, et al.
Publicado: (2020)

Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
por: Yen, Fu‐Shun, et al.
Publicado: (2020)

Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival
por: Villeret, François, et al.
Publicado: (2022)

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022)

Mesenchymal iron deposition is associated with adverse long‐term outcome in non‐alcoholic fatty liver disease
por: Eder, Sebastian K., et al.
Publicado: (2020)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Diagnostic accuracy of fibrosis tests in children with non‐alcoholic fatty liver disease: A systematic review
por: Draijer, Laura G., et al.
Publicado: (2021)

Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008‐2019
por: Sugiyama, Aya, et al.
Publicado: (2021)

Repeated measurements of non‐invasive fibrosis tests to monitor the progression of non‐alcoholic fatty liver disease: A long‐term follow‐up study
por: Balkhed, Wile, et al.
Publicado: (2022)

NAFLD is related to Post‐prandial Triglyceride‐enrichment of HDL Particles in Association with Endothelial and HDL Dysfunction
por: Verwer, Bart J., et al.
Publicado: (2020)

Absence of Bsep/Abcb11 attenuates MCD diet‐induced hepatic steatosis but aggravates inflammation in mice
por: Fuchs, Claudia D., et al.
Publicado: (2020)

Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids
por: de Mello, Vanessa D., et al.
Publicado: (2020)

Interaction between CHOP and FoxO6 promotes hepatic lipid accumulation
por: Kim, Dae Hyun, et al.
Publicado: (2020)

Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
por: Colosimo, Santo, et al.
Publicado: (2021)

Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment
por: Lazure, Patrice, et al.
Publicado: (2022)

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
por: Calleja, José L., et al.
Publicado: (2022)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
por: Björkström, Karl, et al.
Publicado: (2022)

Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity
por: Pavlides, Michael, et al.
Publicado: (2017)

Prescription of statins in suspected non‐alcoholic fatty liver disease and high cardiovascular risk, a population‐based study
por: van den Berg, Eline H., et al.
Publicado: (2019)

Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis
por: Traussnigg, Stefan, et al.
Publicado: (2017)

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
por: Hall, Zoe, et al.
Publicado: (2017)

IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice
por: Harley, Isaac TW, et al.
Publicado: (2014)

Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent
por: De Silva, Sampath, et al.
Publicado: (2018)

The Role of Arterial Stiffness in the Estimation of Cardiovascular Risk in Liver Transplant Recipients
por: Sastre, Lydia, et al.
Publicado: (2021)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study
por: Loomba, Rohit, et al.
Publicado: (2014)

Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice
por: Gariani, Karim, et al.
Publicado: (2015)

Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample
por: Yang, Xu, et al.
Publicado: (2015)

Metabolic profiling of fatty liver in young and middle‐aged adults: Cross‐sectional and prospective analyses of the Young Finns Study
por: Kaikkonen, Jari E., et al.
Publicado: (2016)

Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
por: Decaris, Martin L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r8gupmmrdah5hpuu9r2u765n00